Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Nucleic Acids Research|October 16, 2025
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistanceCordelia D McGehee, X Wei Meng, Xinyan Wu, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Molecular Cancer|October 7, 2024
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitorsAnnapoorna Venkatachalam, Cristina Correia, Kevin L Peterson, et al.
Cancers|December 10, 2021
CHFR and Paclitaxel Sensitivity of Ovarian CancerAndrea E Wahner Hendrickson, Daniel W Visscher, Xiaonan Hou, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 19, 2025
Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinomaXiaonan Hou, Valentina Zanfagnin, Conway Xu, et al.
NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.
Experimental Hematology & Oncology|June 23, 2025
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivityRachel M Hurley, Jill M Wagner, Arun Kanakkanthara, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Pageof 4